Augmedix (AUGX) Stock Price, News & Analysis

Company Overview

Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $2.35 to $2.35
• 50-Day Range: $2.29 to $2.35
• 52-Week Range: $0.73 to $6.25
• Volume: N/A
• Average Volume: 635,746 shs
• Market Capitalization: $115.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.09
• Consensus Rating: Hold

Augmedix Stock Analysis - MarketRank™

Augmedix scored higher than 22% of companies evaluated by MarketBeat, and ranked 851st out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Augmedix has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Augmedix has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Augmedix is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Augmedix is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Augmedix has a P/B Ratio of 4.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AUGX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Augmedix does not currently pay a dividend.

Dividend Growth

Augmedix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for AUGX.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for AUGX on MarketBeat in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Augmedix insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.97% of the stock of Augmedix is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

87.11% of the stock of Augmedix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AUGX Stock Analysis - Frequently Asked Questions

When did Augmedix IPO?

Augmedix (AUGX) raised $40 million in an initial public offering on Tuesday, October 26th 2021. The company issued 10,000,000 shares at a price of $4.00 per share. William Blair, B. Riley Securities, Benchmark and Lake Street acted as the underwriters for the IPO.

Who are Augmedix's major shareholders?

Top institutional investors of Augmedix include Oddo BHF Asset Management Sas (4.95%), Trium Capital LLP (2.41%), HGC Investment Management Inc. (1.69%) and Geode Capital Management LLC (1.14%). Insiders that own company stock include Paul Ginocchio, Emmanuel Krakaris, Ian Shakil and Saurav Chatterjee.
View institutional ownership trends.

What other stocks do shareholders of Augmedix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Augmedix investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Novo Nordisk A/S (NVO).

Company Calendar

• Today: 12/24/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Business services, not elsewhere classified
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:AUGX
• CUSIP: N/A
• CIK: 1769804
• Web: www.augmedix.com
• Phone: 888-669-4885
• Fax: N/A
• Employees: 1,430
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.09
• High Stock Price Target: $5.00
• Low Stock Price Target: $1.50
• Potential Upside/Downside: +31.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-19,170,000.00
• Net Margins: -46.23%
• Pretax Margin: -46.10%
• Return on Equity: -182.36%
• Return on Assets: -43.21%

Debt

• Debt-to-Equity Ratio: 1.48
• Current Ratio: 1.66
• Quick Ratio: 1.66

Sales & Book Value

• Annual Sales: $51.58 million
• Price / Sales: 2.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.56 per share
• Price / Book: 4.20

Miscellaneous

• Outstanding Shares: 48,968,000
• Free Float: 43,596,000
• Market Cap: $115.07 million
• Optionable: Optionable
• Beta: -0.22